Literature DB >> 28083806

New Directions in Anti-Angiogenic Therapy for Glioblastoma.

Nancy Wang1, Rakesh K Jain2, Tracy T Batchelor3,4,5.   

Abstract

Anti-angiogenic therapy has become an important component in the treatment of many solid tumors given the importance of adequate blood supply for tumor growth and metastasis. Despite promising preclinical data and early clinical trials, anti-angiogenic agents have failed to show a survival benefit in randomized controlled trials of patients with glioblastoma. In particular, agents targeting vascular endothelial growth factor (VEGF) appear to prolong progression free survival, possibly improve quality of life, and decrease steroid usage, yet the trials to date have demonstrated no extension of overall survival. In order to improve duration of response and convey a survival benefit, additional research is still needed to explore alternative pro-angiogenic pathways, mechanisms of resistance, combination strategies, and biomarkers to predict therapeutic response.

Entities:  

Keywords:  Angiogenesis; Bevacizumab; Glioblastoma; Glioma; VEGF

Mesh：

Substances：

Year:  2017        PMID： 28083806      PMCID： PMC5398985          DOI： 10.1007/s13311-016-0510-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  125 in total

1.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 3.  Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

Authors:  Karl-Hermann Schlingensiepen; Reimar Schlingensiepen; Andreas Steinbrecher; Peter Hau; Ulrich Bogdahn; Birgit Fischer-Blass; Piotr Jachimczak
Journal:  Cytokine Growth Factor Rev       Date:  2005-12-27       Impact factor: 7.638

Review 4.  CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Authors:  Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

5.  Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Authors:  A Gregory Sorensen; Kyrre E Emblem; Pavlina Polaskova; Dominique Jennings; Heisoog Kim; Marek Ancukiewicz; Meiyun Wang; Patrick Y Wen; Percy Ivy; Tracy T Batchelor; Rakesh K Jain
Journal:  Cancer Res       Date:  2011-11-29       Impact factor: 12.701

6.  New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

Authors:  Thierry Gorlia; Roger Stupp; Alba A Brandes; Roy R Rampling; Pierre Fumoleau; Christian Dittrich; Mario M Campone; Chris C Twelves; Eric Raymond; Monika E Hegi; Denis Lacombe; Martin J van den Bent
Journal:  Eur J Cancer       Date:  2012-03-28       Impact factor: 9.162

7.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

8.  Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.

Authors:  Sheikh A Ali; Wassim M McHayleh; Asif Ahmad; Rajesh Sehgal; Molly Braffet; Mohsin Rahman; Ghassan Bejjani; David M Friedland
Journal:  J Neurosurg       Date:  2008-08       Impact factor: 5.115

9.  Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.

Authors:  Francesca Piludu; Simona Marzi; Andrea Pace; Veronica Villani; Alessandra Fabi; Carmine Maria Carapella; Irene Terrenato; Anna Antenucci; Antonello Vidiri
Journal:  Neuroradiology       Date:  2015-09-12       Impact factor: 2.804

10.  Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Authors:  Jonas Kloepper; Lars Riedemann; Zohreh Amoozgar; Giorgio Seano; Katharina Susek; Veronica Yu; Nisha Dalvie; Robin L Amelung; Meenal Datta; Jonathan W Song; Vasileios Askoxylakis; Jennie W Taylor; Christine Lu-Emerson; Ana Batista; Nathaniel D Kirkpatrick; Keehoon Jung; Matija Snuderl; Alona Muzikansky; Kay G Stubenrauch; Oliver Krieter; Hiroaki Wakimoto; Lei Xu; Lance L Munn; Dan G Duda; Dai Fukumura; Tracy T Batchelor; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205
View more
  39 in total

1.  Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma.

Authors:  Elizabeth C Randall; Begoña G C Lopez; Sen Peng; Michael S Regan; Walid M Abdelmoula; Sankha S Basu; Sandro Santagata; Haejin Yoon; Marcia C Haigis; Jeffrey N Agar; Nhan L Tran; William F Elmquist; Forest M White; Jann N Sarkaria; Nathalie Y R Agar
Journal:  Cancer Res       Date:  2019-11-25       Impact factor: 12.701

Review 2.  Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.

Authors:  Daniel Dubinski; Elke Hattingen; Christian Senft; Volker Seifert; Kevin G Peters; Yvonne Reiss; Kavi Devraj; Karl H Plate
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-25       Impact factor: 6.200

3.  A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.

Authors:  Vinay K Puduvalli; Jing Wu; Ying Yuan; Terri S Armstrong; Elizabeth Vera; Jimin Wu; Jihong Xu; Pierre Giglio; Howard Colman; Tobias Walbert; Jeffrey Raizer; Morris D Groves; David Tran; Fabio Iwamoto; Nicholas Avgeropoulos; Nina Paleologos; Karen Fink; David Peereboom; Marc Chamberlain; Ryan Merrell; Marta Penas Prado; W K Alfred Yung; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

Review 4.  Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.

Authors:  Sanjeev Chawla; Sultan Bukhari; Omar M Afridi; Sumei Wang; Santosh K Yadav; Hamed Akbari; Gaurav Verma; Kavindra Nath; Mohammad Haris; Stephen Bagley; Christos Davatzikos; Laurie A Loevner; Suyash Mohan
Journal:  NMR Biomed       Date:  2022-03-15       Impact factor: 4.478

5.  IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas.

Authors:  Ricardo Gargini; Berta Segura-Collar; María Garranzo-Asensio; Rafael Hortigüela; Patricia Iglesias-Hernández; Daniel Lobato-Alonso; Miguel Moreno-Raja; Santiago Esteban-Martin; Juan M Sepúlveda-Sánchez; Laura Nevola; Pilar Sánchez-Gómez
Journal:  Neurotherapeutics       Date:  2022-01-31       Impact factor: 6.088

Review 6.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

Review 7.  Glioma Cell and Astrocyte Co-cultures As a Model to Study Tumor-Tissue Interactions: A Review of Methods.

Authors:  Ivan V Chekhonin; Dimitry A Chistiakov; Nadezhda F Grinenko; Olga I Gurina
Journal:  Cell Mol Neurobiol       Date:  2018-05-10       Impact factor: 5.046

8.  Evaluating the effect of Avastin on breast cancer angiogenesis using synchrotron radiation.

Authors:  Shengmei Gu; Jingyan Xue; Yan Xi; Rongbiao Tang; Wei Jin; Jia-Jian Chen; Xi Zhang; Zhi-Min Shao; Jiong Wu
Journal:  Quant Imaging Med Surg       Date:  2019-03

9.  Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.

Authors:  Xin Cui; Renee-Tyler Tan Morales; Weiyi Qian; Haoyu Wang; Jean-Pierre Gagner; Igor Dolgalev; Dimitris Placantonakis; David Zagzag; Luisa Cimmino; Matija Snuderl; Raymond H W Lam; Weiqiang Chen
Journal:  Biomaterials       Date:  2018-02-03       Impact factor: 12.479

Review 10.  Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.

Authors:  Ali S Arbab; Mohammad H Rashid; Kartik Angara; Thaiz F Borin; Ping-Chang Lin; Meenu Jain; Bhagelu R Achyut
Journal:  Int J Mol Sci       Date:  2017-12-16       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.